European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3.
duodenal neuroendocrine tumours
gastric carcinoids
guidelines
management
prognosis
Journal
Journal of neuroendocrinology
ISSN: 1365-2826
Titre abrégé: J Neuroendocrinol
Pays: United States
ID NLM: 8913461
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
09
05
2023
received:
27
04
2023
accepted:
10
05
2023
medline:
28
8
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
The aim of the present guidance paper was to update the previous ENETS guidelines on well-differentiated gastric and duodenal neuroendocrine tumours (NETs), providing practical guidance for specialists in the diagnosis and management of gastroduodenal NETs. Type II gastric NETs, neuroendocrine carcinomas (NECs), and functioning duodenal NETs are not covered, since they will be discussed in other ENETS guidance papers.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13306Informations de copyright
© 2023 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
Références
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342. doi:10.1001/jamaoncol.2017.0589
Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104(4):994-1006. doi:10.1016/0016-5085(93)90266-f
Sato Y, Iwafuchi M, Ueki J, et al. Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection. Dig Dis Sci. 2002;47(3):579-585.
Fossmark R, Calvete O, Mjønes P, Benitez J, Waldum HL. ECL-cell carcinoids and carcinoma in patients homozygous for an inactivating mutation in the gastric H(+) K(+) ATPase alpha subunit. APMIS. 2016;124(7):561-566. doi:10.1111/apm.12546
Trinh VQ, Shi C, Ma C. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis. Histopathology. 2020;77(6):865-876. doi:10.1111/his.14220
Borbath I, Pape UF, Deprez PH, et al. ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. J Neuroendocrinol. 2022;34(3):e13105. doi:10.1111/jne.13105
La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms. In: Fukayama M, Rugge M, Washington M, eds. Digestive System Tumours. WHO Classification of Tumours, Vol. 1. IARC Press; 2019:104-109.
Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770-1786. doi:10.1038/s41379-018-0110-y
Esposito G, Angeletti S, Cazzato M, et al. Narrow band imaging characteristics of gastric polypoid lesions: a single-center prospective pilot study. Eur J Gastroenterol Hepatol. 2020 Jun;32(6):701-705. doi:10.1097/MEG.0000000000001697
Rinzivillo M, Panzuto F, Esposito G, Lahner E, Signore A, Annibale B. Usefulness of 68-gallium PET in type I gastric neuroendocrine neoplasia: a case series. J Clin Med. 2022;11(6):1641. doi:10.3390/jcm11061641
Tsolakis AV, Ragkousi A, Vujasinovic M, Kaltsas G, Daskalakis K. Gastric neuroendocrine neoplasms type 1: a systematic review and meta-analysis. World J Gastroenterol. 2019;25(35):5376-5387. doi:10.3748/wjg.v25.i35.5376
Exarchou K, Hu H, Stephens NA, et al. Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter. Endocrine. 2022 Oct;78(1):186-196. doi:10.1007/s12020-022-03143-3
Chung CS, Tsai CL, Chu YY, et al. Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: a digestive endoscopy Society of Tawian (DEST). Medicine (Baltimore). 2018;97(38):e12101. doi:10.1097/MD.0000000000012101
Chin JL, O'Connell J, Muldoon C, et al. Selective resection of type 1 gastric neuroendocrine neoplasms and the risk of progression in an endoscopic surveillance programme. Dig Surg. 2021;38(1):38-45. doi:10.1159/000510962
Panzuto F, Magi L, Esposito G, Rinzivillo M, Annibale B. Comparison of endoscopic techniques in the management of type I gastric neuroendocrine neoplasia: a systematic review. Gastroenterol Res Pract. 2021 Mar;30(2021):6679397-6. doi:10.1155/2021/6679397
Noh JH, Kim DH, Yoon H, et al. Clinical outcomes of endoscopic treatment for type 1 gastric neuroendocrine tumor. J Gastrointest Surg. 2021;25(10):2495-2502. doi:10.1007/s11605-021-04997-0
Sato Y, Takeuchi M, Hashimoto S, et al. Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection. Hepatogastroenterology. 2013;60(126):1524-1529. doi:10.5754/hge121185
Pimentel-Nunes P, Libânio D, Bastiaansen BAJ, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) guideline-update 2022. Endoscopy. 2022;54(6):591-622. doi:10.1055/a-1811-7025
Esposito G, Cazzato M, Rinzivillo M, et al. Management of type-I gastric neuroendocrine neoplasms: a 10-years prospective single Centre study. Dig Liver Dis. 2022;54(7):890-895. doi:10.1016/j.dld.2021.11.012
Rossi RE, Invernizzi P, Mazzaferro V, Massironi S. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: a systematic review and meta-analysis. United European Gastroenterol J. 2020;8(2):140-147. doi:10.1177/2050640619890465
Boyce M, Moore AR, Sagatun L, et al. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br J Clin Pharmacol. 2017;83(3):466-475. doi:10.1111/bcp.13146
Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European helicobacter and microbiota study group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-388. doi:10.1055/a-0859-1883
Vanoli A, La Rosa S, Miceli E, et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology. 2018;107(2):114-126. doi:10.1159/000489902
Ye H, Yuan Y, Chen P, Zheng Q. Risk factors for metastasis and survival of patients with T1 gastric neuroendocrine carcinoma treated with endoscopic therapy versus surgical resection. Surg Endosc. 2022;36(8):6162-6169. doi:10.1007/s00464-022-09190-1
Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011. doi:10.1210/jc.2012-1230
Exarchou K, Kamieniarz L, Tsoli M, et al. Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms? Endocrine. 2021;74(2):421-429. doi:10.1007/s12020-021-02775-1
Hirasawa T, Yamamoto N, Sano T. Is endoscopic resection appropriate for type 3 gastric neuroendocrine tumors? Retrospective Multicenter Study. Dig Endosc. 2021;33(3):408-417. doi:10.1111/den.13778
Min BH, Hong M, Lee JH, et al. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. Br J Surg. 2018;105(11):1480-1486. doi:10.1002/bjs.10901
Hanna A, Kim-Kiselak C, Tang R, et al. Gastric neuroendocrine tumors: reappraisal of type in predicting outcome. Ann Surg Oncol. 2021;28(13):8838-8846. doi:10.1245/s10434-021-10293-7
Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22(30):6817-6828. doi:10.3748/wjg.v22.i30.6817
Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072. doi:10.1200/JCO.2007.15.4377
Fitzgerald TL, Dennis SO, Kachare SD, Vohra NA, Zervos EE. Increasing incidence of duodenal neuroendocrine tumors: incidental discovery of indolent disease? Surgery. 2015 Aug;158(2):466-471. doi:10.1016/j.surg.2015.03.042
Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014:13-27. doi:10.1196/annals.1294.002
Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115-154. doi:10.1007/s12022-022-09708-2
Sorbye H, Grande E, Pavel M, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35(3). doi:10.1111/jne.13249
WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. International Agency for Research on Cancer; 2022.
Mamilla D, Manukyan I, Fetsch PA, Pacak K, Miettinen M. Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors. Hum Pathol. 2020;103:72-82. doi:10.1016/j.humpath.2020.07.010
Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. Barcelona consensus conference participants. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95(2):74-87. doi:10.1159/000335595
Okubo Y, Yokose T, Motohashi O, et al. Duodenal rare neuroendocrine tumor: Clinicopathological characteristics of patients with Gangliocytic Paraganglioma. Gastroenterol Res Pract. 2016;2016:5257312. doi:10.1155/2016/5257312
Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol. 2005;19(5):675-697. doi:10.1016/j.bpg.2005.05.009
Stamm B, Hedinger CE, Saremaslani P. Duodenal and ampullary carcinoid tumors. A report of 12 cases with pathological characteristics, polypeptide content and relation to the MEN I syndrome and von Recklinghausen's disease (neurofibromatosis). Virchows Arch A Pathol Anat Histopathol. 1986;408(5):475-489. doi:10.1007/BF00705301
Exarchou K, Moore AR, Smart HL, Duckworth CA, Howes N, Pritchard DM. A "watch and wait" strategy involving regular endoscopic surveillance is safe for many patients with small, sporadic, grade 1, non-ampullary, non-functioning duodenal neuroendocrine tumours. Neuroendocrinology. 2021;111(8):764-774. doi:10.1159/000511613
Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med. 1994;97(5):436-444. doi:10.1016/0002-9343(94)90323-9
Chin JL, O'Toole D. Diagnosis and management of upper gastrointestinal neuroendocrine tumors. Clin Endosc. 2017;50(6):520-529. doi:10.5946/ce.2017.181
Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol. 1999;17(2):615-630. doi:10.1200/JCO.1999.17.2.615
Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108(6):1637-1649. doi:10.1016/0016-5085(95)90124-8
Tsai SD, Kawamoto S, Wolfgang CL, Hruban RH, Fishman EK. Duodenal neuroendocrine tumors: retrospective evaluation of CT imaging features and pattern of metastatic disease on dual-phase MDCT with pathologic correlation. Abdom Imaging. 2015;40(5):1121-1130. doi:10.1007/s00261-014-0322-7
Imperiale A, Averous G, Helali M, et al. Limited role of carbidopa-assisted 18F-FDOPA PET/CT in patients with sporadic non-functional gastroduodenal neuroendocrine neoplasms. Ann Nucl Med. 2019;33(9):697-707. doi:10.1007/s12149-019-01378-1
Sharma A, Das CJ, Makharia GK, Arora G, Kumar R. Comparison of contrast-enhanced CT + CT enterography and 68Ga-DOTANOC PET/CT in gastroenteropancreatic neuroendocrine tumors. Clin Nucl Med. 2020;45(11):848-853. doi:10.1097/RLU.0000000000003188
Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105(3):212-244. doi:10.1159/000471879
Niederle B, Selberherr A, Bartsch DK, et al. Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome-an international consensus Statement. Neuroendocrinology. 2021;111(7):609-630. doi:10.1159/000511791
Margonis GA, Samaha M, Kim Y, et al. A multi-institutional analysis of duodenal neuroendocrine tumors: tumor biology rather than extent of resection dictates prognosis. J Gastrointest Surg. 2016;20(6):1098-1105. doi:10.1007/s11605-016-3135-x
Tsujimoto H, Ichikura T, Nagao S, et al. Minimally invasive surgery for resection of duodenal carcinoid tumors: endoscopic full-thickness resection under laparoscopic observation. Surg Endosc. 2010;24(2):471-475. doi:10.1007/s00464-009-0574-4
Mandair D, Kamieniarz L, Pizanias M, et al. Diagnostic features and management options for duodenal neuroendocrine neoplasms: a retrospective, multi-centre study. Sci Rep. 2022;12(1):15762. doi:10.1038/s41598-022-19738-9
Exarchou K, Howes N, Pritchard DM. Systematic review: management of localised low-grade upper gastrointestinal neuroendocrine tumours. Aliment Pharmacol Ther. 2020;51(12):1247-1267. doi:10.1111/apt.15765
Dogeas E, Cameron JL, Wolfgang CL, et al. Duodenal and ampullary carcinoid tumors: size predicts necessity for lymphadenectomy. J Gastrointest Surg. 2017 Aug;21(8):1262-1269. doi:10.1007/s11605-017-3448-4
Ruff SM, Standring O, Wu G, et al. Ampullary neuroendocrine tumors: insight into a rare histology. Ann Surg Oncol. 2021;28(13):8318-8328. doi:10.1245/s10434-021-10371-w
Massironi S, Campana D, Partelli S, et al. Heterogeneity of duodenal neuroendocrine tumors: an Italian multi-center experience. Ann Surg Oncol. 2018;25(11):3200-3206. doi:10.1245/s10434-018-6673-5
Zhang XF, Wu XN, Tsilimigras DI, et al. Duodenal neuroendocrine tumors: impact of tumor size and total number of lymph nodes examined. J Surg Oncol. 2019;120(8):1302-1310. doi:10.1002/jso.25753
Fujii Y, Tzeng CW, Chiang YJ, et al. Incidence of lymph node metastases and impact of radical surgery for duodenal neuroendocrine tumors. J Surg Res. 2021;268:419-431. doi:10.1016/j.jss.2021.06.085
Pommergaard HC, Nielsen K, Sorbye H, et al. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. J Neuroendocrinol. 2021;33(5):e12967. doi:10.1111/jne.12967
Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968-977. doi:10.1016/S0140-6736(15)00817-X
de Mestier L, Lamarca A, Hernando J, et al. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. Endocr Relat Cancer. 2021;28(8):549-561. doi:10.1530/ERC-21-0109
Janson ET, Knigge U, Dam G, et al. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2021;60(7):931-941. doi:10.1080/0284186X.2021.1921262
Johnbeck CB, Knigge U, Kjaer A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10(14):2259-2277. doi:10.2217/fon.14.139